APT-F2
- Generic Name
- APT-F2
A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Ribomic USA Inc
- Target Recruit Count
- 40
- Registration Number
- NCT04640272
- Locations
- 🇺🇸
Retinal Research Institute, LLC, Phoenix, Arizona, United States
🇺🇸Valley Retina Institute, McAllen, Texas, United States
🇺🇸Retinal Medical Consultants Group, Sacramento, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath